Víctor Alfonso Jiménez Díaz: SAPT or DAPT in Valve-in-Valve TAVI? Walking a Fine Line
Víctor Alfonso Jiménez Díaz, Director, Cardiovascular Research Unit, Hospital Álvaro Cunqueiro at Hospital Álvaro Cunqueiro, University Hospital Complex of Vigo, shared a post on LinkedIn:
“SAPT or DAPT in Valve-in-Valve TAVI? Walking a Fine Line
Antithrombotic therapy after TAVI remains one of the most complex challenges in structural heart interventions. Although the POPular TAVI trial shifted the balance toward single antiplatelet therapy (SAPT) in the general population, can we apply the same logic to Valve-in-Valve (ViV) procedures?
We have just published our editorial comment in JACC: Cardiovascular Interventions: “Still Walking a Fine Line,” where we analyze the interesting study by Bendandi et al. on the use of SAPT vs. DAPT in ViV procedures.
Why is the ViV scenario different?
-In ViV, altered anatomy and hemodynamic limitations can amplify thrombotic risk.
-Evidence from native TAVI is not always extrapolable to patients with failed bioprostheses.
-The balance between bleeding risk and leaflet thrombosis is, now more than ever, a “fine line.”
This editorial highlights the urgent need for subgroup-specific data and individualized decision-making.
Congratulations to my colleague Cláudio Espada Guerreiro for this analysis and to Francesco Bendandi, Palmerini Tullio, Federico De Marco, Cosmo Godino, Chiara Fraccaro, Marco Barbanti, francesco maisano, Francesco Saia and the entire Italian team for the original research.
Read the full editorial here”
Title: Dual vs Single Antiplatelet Therapy After Valve-in-Valve TAVR: Still Walking a Fine Line
Authors: Victor Alfonso Jimenez Diaz, Claudio Guerreiro
Get the latest updates with Hemostasis Today.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC
-
Apr 9, 2026, 18:21New Clinical Practice Guideline on Anticoagulant Prophylaxis in Pediatric Patients at Risk of VTE – ISTH
-
Apr 9, 2026, 16:40We Are Incredibly Grateful to Our Volunteers – Hemophilia of Georgia
-
Apr 9, 2026, 15:10Christoffer Gebhardt: Can Anticoagulation Improve Outcomes in Melanoma Therapy?
-
Apr 9, 2026, 15:09National Institutes of Health Addresses VTE Research Funding Gap – JTH
-
Apr 9, 2026, 15:08Alice Assinger: Recruiting PhD Students for NET-IT Doctoral Program in Vienna
-
Apr 9, 2026, 15:07Hannah Cohen: A Novel Approach to Post-Stroke Gait Rehabilitation
-
Apr 9, 2026, 15:07Shehab Mohamed: A Single-Center Experience on Stroke Risk in Polycythemia Vera